Given the recent positive data from Immunovant's mid-stage study for batoclimab in Graves' disease, I foresee a downturn in IMVT's stock due to overex...
Read
More
Given the recent positive data from Immunovant's mid-stage study for batoclimab in Graves' disease, I foresee a downturn in IMVT's stock due to overexcitement in the market. This makes it a suitable candidate for a short position as expectations may not align with long-term performance.